Key Takeaways
- 96% of patients with ovarian or related cancer who had comprehensive genetic and tumor testing had at least one finding that could potentially help guide treatment or identify a clinical trial opportunity
- Various tests uncovered different information, highlighting the value of a coordinated testing strategy guided by a genetic counselor
- Findings presented this week at the National Society of Genetic Counselors (NSGC) 45th Annual Conference
BALTIMORE – Nov. 12, 2026 – Nearly all patients with ovarian, fallopian tube or primary peritoneal cancer who had comprehensive genetic and tumor testing had at least one finding that could potentially help guide treatment or identify a clinical trial opportunity, according to new research presented at the National Society of Genetic Counselors (NSGC) 45th Annual Conference.
The findings suggest that considering multiple types of genetic and tumor testing may give patients and their care teams a more complete picture of treatment options than relying on individual tests alone.
“Different tests can reveal different pieces of information that matter for a patient’s care, and this study shows why it’s important to look at those pieces together,” said Carrie Haverty, MS, CGC, president of the National Society of Genetic Counselors. “Genetic counselors can help coordinate and interpret this complex testing so potentially important findings aren’t missed, and patients and their care teams understand what the results may mean for treatment, clinical trials and their families.”
Researchers looked at patients who received four complementary types of testing: germline testing, which looks for inherited cancer-related genetic changes; Homologous Recombination Deficiency (HRD) testing and tumor genomic profiling, which look for characteristics or changes in the tumor that may help guide treatment; and folate receptor alpha (FRα) testing, which can help determine whether certain patients may be eligible for a targeted treatment.
Searching a large clinical research registry, researchers identified 116,181 people diagnosed with ovarian, fallopian tube or primary peritoneal cancer. Of those, 1,053 had records showing they completed all four types of testing at Myriad Genetics. Among this comprehensively tested group, 1,016 (96%) had at least one finding with potential treatment implications. More than half, 602 (57%) had at least one positive result relevant to recommended treatment, while 414 (41%) had tumor findings associated with potential eligibility for a clinical trial. For example, 11% had an inherited pathogenic genetic variant, most commonly in BRCA1 or BRCA2, while 39% tested positive for FRα expression.
Different tests can open different doors. For example, a BRCA1 or BRCA2 variant may help clinicians decide whether PARP inhibitor treatment may be beneficial. And certain patients with platinum-resistant cancer who have FRα-positive tumors may be eligible for an FRα-directed treatment. Tumor profiling also may uncover biomarkers associated with immunotherapy or match a patient to a clinical trial.
Yet these tests are often ordered separately by different providers. That can lead to missed tests, delayed results or incomplete information when treatment decisions are being made.
“Our study suggests that a coordinated approach may help reduce barriers created by fragmented test ordering and multiple appointments, with a goal of improving access to precision medicine,” said Cameron Friedman, MS, CGC, lead author of the study and an oncology medical science liaison at Myriad Genetics. “Genetic counselors can serve as essential partners in coordinating testing, interpreting complex findings and helping patients and providers understand what the results may mean for care and for their families.”
News releases may contain updated data or language that does not match what is reported in the abstract.
# # #
Note to editors: Media interested in viewing study abstracts, interviewing authors and/or attending sessions at the NSGC Annual Conference can contact NSGC’s PR team at NSGCPR@pcipr.com.
About the National Society of Genetic Counselors
NSGC is the leading voice, authority and advocate for the genetic counseling profession. Membership represents more than 5,000 masters-level health professionals, who are committed to ensuring that the public has access to genetic counseling and genetic testing. For more information, visit www.nsgc.org.
# # #